Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use

US10301377B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Barney Graham · Rockville, US
• Wing-Pui Kong · Germantown, US
• Kayvon Modjarrad · Chevy Chase Section Five, US
• Lingshu Wang · North Potomac, US
• Wei Shi · 安丰镇, CN
• Michael Gordon Joyce · Washington, US
• Masaru Kanekiyo · Bethesda, US
• John Mascola · Rockville, US

Key dates

• Filing date: Feb 24, 2016
• Grant date: May 28, 2019
• Expiry date: Feb 24, 2036

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/165
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods of inducing an immune response in a subject to the Middle East respiratory syndrome coronavirus (MERS-CoV) are provided. In several embodiments, the immune response is a protective immune response that inhibits or prevents MERS-CoV infection in the subject. Recombinant MERS-CoV polypeptides and nucleic acid molecules encoding same are also provided. Additionally, neutralizing antibodies that specifically bind to MERS-CoV S protein and antigen binding fragments thereof are disclosed. The antibodies and antigen binding fragments are useful, for example, in methods of detecting MERS-CoV S protein in a sample or in a subject, as well as methods of preventing and treating a MERS-CoV infection in a subject.